Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2014-09-15, 12:31:02 | version 1.32.01
7. Rijlaarsdam JU, Bakels V, van Oostveen JW, et al. Demonstration of clonal immunoglobulin gene rearrangements in cutaneous B-cell lymphomas and pseudo-B-cell lymphomas: differential diagnostic and pathogenetic aspects. J Invest Dermatol 1992; 99: 749-754. 8. Geelen FAMJ, Vermeer MH, van der Putte SCJ, et al. Bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-dependent. J Clin Oncol 1998; 16: 2080-5. 9. Tensen CP, Vermeer MH, van der Stoop PM, et al. Epidermal Interferon-? inducible protein-10 (IP-10) and monokine induced by ?-interferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T-cell lymphomas. J Invest Dermatol 1998; 111: 222-6. 10. Flier J, Boorsma DM, van Beek PJ, et al. Differential expression of CXCR3 targeting chemokines IP-10, Mig anand IP-9/I-TAC in different types of skin inflammation. J Pathol 2001; 194: 398-405. Skin tissue engineering and wound healing One of the most advanced fields of tissue engineering is in the area of skin. In 2000 biochemist and cell biologist Sue Gibbs joined the department to become the new head of the research laboratory. Originally from the United Kingdom, she had been involved in studies on the differentiation of cultured epidermal keratinocytes and in-vitro reconstructed skin models in Leiden as a member of Maja Ponec’s group since 1986. Gibbs continued this line of research after moving to Amsterdam, where she deve- loped an autologous epidermal-dermal bilayered skin substitute for treating therapy resistant (leg) ulcers. An extended Phase I clinical study showed that this construct was safe to use and first efficacy results showed that the skin substitute stimulated wound closure and revitalized the inert wound bed.[1] This work lead to the foundation of spin-off company A-Skin and the development of Tiscover® , an autologous skin construct.[2] A multi-center Phase II study with Tiscover® is currently under way. Another construct developed by Gibbs and her co-workers in collaboration with the Association of Dutch Burns Centers, consists of proliferating keratinocytes and melanocytes in a collagen/elastin carrier, used for treating third-degree burns. Other projects include studies on the effects of dermal cells and keratinocytes on burn wounds, allergen-induced behaviour of Langerhans cells and identi- fication of contact sensitizers in skin equivalents, an in-vitro hypertrophic scar model to identify novel drug targets and a model to study dendritic cell biology and the innate immune system.[3-7] An important advantage of the skin constructs developed by Gibbs and her co-workers lies in the fact that they provide an alternative to animal testing, which is in compliance with the ‘3 Rs’ (Replacement, Reduction and Refinement) of animal experimentation. In recent years the laboratory has become involved in studies on the regenerative properties of oral mucosa, in collaboration with the Department of Oral Cell Biology of the Academic Center for Dentistry in Amsterdam (ACTA). In July 2012 Sue Gibbs (1963) was appointed the Fenna Diemer Lindeboom Chair as Professor of Skin and Mucosa Regenerative Medicine at VUmc and ACTA. Currently, Gibbs and her group are addressing basic research questions, such as why oral wounds heal quickly with relatively little scar formation, whereas skin wounds heal relatively slowly, and often with adverse scar formation. The mechanisms underlying the clear differences in innate and adaptive immunology between skin and mucosa will also be studied. 123 BWEADVSMGFINCORR:Opmaak 1 21-07-2014 17:40 Pagina 123